Basit öğe kaydını göster

dc.contributor.advisorBaydar, Terken
dc.contributor.authorMuhammetli, Sara
dc.date.accessioned2023-03-16T11:19:38Z
dc.date.issued2023
dc.date.submitted2023-01-19
dc.identifier.citation1. Demir F. Ağır Metal Toksisitesinin Kanser ile İlişkisi. Gaziosmanpasa J Sci Res. 2021;10(1):21–9. 2. Akbal A, Reşorlu H, Savaş Y. Ağır Metallerin Kemik Doku Üzerine Toksik Etkileri. Turk Osteoporoz Derg. 2015;21(1):30–3. 3. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: A review. Rev Environ Health. 2009;24(1):15– 45. 4. Gidlow DA. Lead toxicity. Occup Med (Chic Ill). 2015;65(5):348–56. 5. BAŞ L, DEMET Ö. Çevresel Toksikoloji Yönünden Bazı Ağır Metaller. Çevre Derg. 1992;5:42–6. 6. Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med. 2000;38(3):244–54. 7. García-Lestón Julia J, Méndez J, Pásaro E, Laffon B. Genotoxic effects of lead: An updated review. Environ Int. 2010;36(6):623–36. 8. Hodson ME. Heavy metals - Geochemical bogey men? Environ Pollut. 2004;129(3):341–3. 9. Riva MA, Belingheri M, De Vito G, Lucchini R. Bernardino Ramazzini (1633- 1714). J Neurol. 2018;265:2164–5. 10. TATAR ÇP. Kurşun Maruziyetinin İş Sağlığı ve Güvenliği Açısından Değerlendirilmesi (Akü, Maden ve Metal İşyerlerinde). T.C. ÇALIŞMA VE SOSYAL GÜVENLİK BAKANLIĞI İŞ SAĞLIĞI VE GÜVENLİĞİ GENEL MÜDÜRLÜĞÜ; 2014. 11. Aktepe N. Kurşun Ağır Metaline Maruz Kalma Yolları ve Sağlığa Olan Olumsuz Etkileri. Içinde: Goncagül G, Günaydın E, editörler. Sağlık Bilimleri Alanında Güncel Araştırmalar. Ankara: Duvar Yayınları; 2020. s. 115–34. 12. ULUSAL GERİ DÖNÜŞÜM STRATEJİ BELGESİ VE EYLEM PLANI 2014- 2017. Ankara; 2017. 13. Caylak E. Lead Toxication and Oxidative Stress in Children and Antioxidant Effects of Thiol Compounds. Tuberculin Ski Test Child. 2010;10(1):13–23. 14. Sonçağ A, Yurdakök K. Intrauterin Toksik Ağır Metal Etkilenimi. Çocuk Sağlığı ve Hast Derg. 2010;53:145–58. 15. Rusyniak DE, Arroyo A, Acciani J, Froberg B, Kao L, Furbee B. Heavy metal poisoning: management of intoxication and antidotes. Mol Clin Environ Toxicol. 2010;100:365–96. 16. Wani AL, Ara A, Usmani JA. Lead toxicity: A review. Interdiscip Toxicol. 2015;8(2):55–64. 17. Sipahi H, Girgin G, Palabiyik SS, Tutkun E, Yilmaz OH, Baydar T. Possible changes of New-Generation inflammation markers with occupational lead exposure. J Occup Health. 2017;59(4):345–51. 68 18. Cao Y, Skaug MA, Andersen O, Aaseth J. Chelation therapy in intoxications with mercury, lead and copper. J Trace Elem Med Biol. 2015;31:188–92. 19. Maden M, Köse SI. Biyomarkerlar ve Klinik Kullanımları. Dicle Üniversitesi Veterinerlik Fakütesi Derg. 2013;2(1):1–8. 20. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–6. 21. Baydar T, Palabıyık S, Şahin G. Neopterin: günümüzün popüler biyogöstergesi mi? Türkiye Klin. 2009;29(5):1280–91. 22. Hamerlinck FF V. Neopterin : a review. Experimantal Dermatology. 1999;8:167–76. 23. SAKURAI A, GOTO M. Neopterin: Isolation from Human Urine. J Biochem. 1967;61(1):142–5. 24. Schroecksnadel K, Murr C, Winkler C, Wirleitner B, Fuith LC, Fuchs D. Neopterin to monitor clinical pathologies involving interferon-γ production. Pteridines. 2004;15(3):75–90. 25. Hoffmann G, Schobersberger W. Neopterin: A mediator of the cellular immune system. Pteridines. 2004;15(3):107–12. 26. Engin AB, Tuzun D, Sahin G. Evaluation of Pteridine Metabolism in Battery Workers Chronically Exposed to Lead. Hum Exp Toxicol. 2006;25:353–9. 27. UNEP. Final review of scientific information on lead [Internet]. Available at: https://wedocs.unep.org/bitstream/handle/20.500.11822/27635/LeadRev.pdf 28. Lead, elemental [Internet]. Available at: https://pubchem.ncbi.nlm.nih.gov/source/hsdb/231 29. Lead (Element) [Internet]. Available at: https://pubchem.ncbi.nlm.nih.gov/element/82#section=History 30. LEAD [Internet]. Available at: https://www.ilo.org/dyn/icsc/showcard.display?p_version=2&p_card_id=0052 31. Ulusal Atık Yönetimi ve Eylem Planı 2023. T.C. Çevre ve Şehircilik Bakanlığı. 2016. 32. King M, Ramachandran V, Prengaman RD, DeVito SC, Breen J, Updated by Staff. Lead and Lead Alloys. Kirk-Othmer Encycl Chem Technol. 2005; 33. Abadin H, Ashizawa A, Stevens Y-W, Llados F, Diamond G, Sage G, vd. Toxicological profile for lead. 2020. 34. Casaret L, Klaassen C, Doull J. Toxic effects of metals. Içinde: Klaassen CD, editör. Casarett & Doull’s Toxicology: The Basic Science of Poisons. Seventh. Kansas City; 2008. s. 931–81. 35. Lane RE. The Care of the Lead Worker. Br J Ind Med. 1949;6(3):125–43. 36. Needleman H. Lead poisoning. Annu Rev Med. 2004;55(1):209–22. 37. Garza A, Vega R, Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit. 2006;12(3):57–65. 69 38. Cleveland LM, Minter ML, Cobb KA, Scott AA, German VF. Lead hazards for pregnant women and children: Part 1. Am J Nurs. 2008;108(10):40–9. 39. CDC. Preventing lead poisoning in children. 1991. 40. Winneke G, Brockhaus A, Ewers U, Krämer U, Neuf M. Results from the European multicenter study on lead neurotoxicity in children: Implications for risk assessment. Neurotoxicol Teratol. 1990;12(5):553–9. 41. Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, vd. The relationship of bone and blood lead to hypertension: The normative aging study. Jama. 1996;275(15):1171–6. 42. Batuman V. Lead Nephropathy, Gout and Hypertension. Am J Med Sci. 1993;305(4):241–7. 43. Schwartz J. Lead, blood pressure, and cardiovascular disease in men. Arch Environ Health. 1995;50(1):31–7. 44. Nash D, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, Silbergeld EK. Blood Lead, Blood Pressure, and Hypertension in Perimenopausal and Postmenopausal Women. 2003;289(12):1523–32. 45. Rothenberg SJ, Kondrasho V, Manalo M, Jiang J, Cuellar R, Garcia M, vd. Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol. 2002;156(12):1079–87. 46. Dietert RR, Lee JE, Hussain I, Piepenbrink M. Developmental immunotoxicology of lead. Toxicol Appl Pharmacol. 2004;198(2):86–94. 47. Karmaus W, Brooks KR, Nebe T, Witten J, Obi-Osius N, Kruse H. Immune function biomarkers in children exposed to lead and organochlorine compounds: A cross-sectional study. Environ Heal A Glob Access Sci Source. 2005;4:1–10. 48. Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett. 1989;46(1–3):153–62. 49. Borja-Aburto VH, Hertz-Picciotto I, Lopez MR, Farias P, Rios C, Blanco J. Blood lead levels measured prospectively and risk of spontaneous abortion. Am J Epidemiol. 1999;150(6):590–7. 50. McClain RM, Becker BA. Teratogenicity, fetal toxicity, and placental transfer of lead nitrate in rats. Toxicol Appl Pharmacol. 1975;31(1):72–82. 51. Rousseau MC, Straif K, Siemiatycki J. IARC carcinogen update. Environ Health Perspect. 2005;113(9):580–3. 52. Cocco P, Dosemeci M, Heineman EF. Brain Cancer and Occupational Exposure to Lead. J Occup Environ Med. 1998;40(11):937–42. 53. Anttila A, Heikkila P, Pukkala E, Nykyri E, Kauppinen T, Hernberg S, vd. Excess lung cancer among workers exposed to lead. Scand J Work Environ Heal. 1995;21(6):460–9. 54. Patra RC, Rautray AK, Swarup D. Oxidative stress in lead and cadmium toxicity and its amelioration. Vet Med Int. 2011;2011. 70 55. Pounds JG, Long GJ, Rosen JF. Cellular and molecular toxicity of lead in bone. Environ Health Perspect. 1991;91:17–32. 56. Vahter M, Berglund M, Åkesson A, Lidén C. Metals and women’s health. Environ Res. 2002;88(3):145–55. 57. Kianoush S, Sadeghi M, Balali-Mood M. Recent advances in the clinical management of lead poisoning. Acta Med Iran. 2015;53(6):327–36. 58. Januzzi AT. Mesleki Kurşun Maruziyetine Bağlı DNA Hasarlarının Değerlendirilmesi. İstanbul Üniversitesi Sağlık Bilimleri Estitüsü; 2013. 59. Sachdeva C, Thakur K, Sharma A, Sharma KK. Lead: Tiny but Mighty Poison. Indian J Clin Biochem. 2018;33(2):132–46. 60. Laraque D, Trasande L. Lead Poisoning : Century Challenges. Pediatr Rev. 2005;26(12). 61. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G. Neopterin. Biochemistry—methods—clinical application. 1992. 62. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29(3–4):307–44. 63. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010;287:13–22. 64. Fuchs D, Weiss G, Wachter H. Neopterin, Biochemistry and Clinical Use as a Marker for Cellular Immune Reactions. Int Arch Allergy Immunol. 1993;101:1–6. 65. Fuchs D, Stahl-Hennig C, Gruber A, Murr C, Hunsmann G, Wachter H. Neopterin - its clinical use in urinalysis. Kidney Interational Suppl. 1994;47:8– 11. 66. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther. 2001;26(5):319–29. 67. Ceyhan AM, Yildirim M, Ceyhan BM, Sütçü R. Psoriasisde serum neopterin ve TNF-α düzeyleri ve hastalik şiddeti ile ı̇lişkisi. Turkderm Deri Hast ve Frengi Ars. 2012;46(1):7–10. 68. Baydar T, Yuksel O, Sahin TT, Dikmen K, Girgin G, Sipahi H, vd. Neopterin as a prognostic biomarker in intensive care unit patients. J Crit Care [Internet]. 2009;24(3):318–21. Available at: http://dx.doi.org/10.1016/j.jcrc.2008.06.013 69. Sahin T, Yuksel O, Girgin G, Sipahi H, Dikmen K, Azili C, vd. Is neopterin level a predictive and differential biomarker in patients with thyroid disorders? J Endocrinol Invest. 2009;32:147–9. 70. Yuksel O, Sahin T, Girgin G, Sipahi H, Dikmen K, Samur O, vd. Neopterin, catalase and superoxide dismutase in females with benign and malignant breast tumors. Pteridines. 2007;18(4):132–8. 71. Müller MM, Curtius HC, Herold M, Huber CH. Neopterin in clinical practice. 71 Clin Chim Acta. 1991;201(1–2):1–16. 72. 6-Biopterin [Internet]. Available at: https://www.sigmaaldrich.com/TR/en/product/sigma/b2517 73. Maršálek P, Svoboda M, Smutná M, Blahová J, Večerek V. Neopterin and biopterin as biomarkers of immune system activation associated with castration in piglets. J Anim Sci. 2011;89(6):1758–62. 74. Uçar T. Fabry Hastalarında Serum Neopterin, Biopterin, Triptofan ve Kinürenin Düzeylerinin Araştırılması. İstanbul Üniversitesi; 2022. 75. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009;32(3):457. 76. Girgin G, Baydar T, Sahin TT, Palabiyik SS, Sipahi H, Yuksel O, vd. Urinary Biopterin Levels and Blood Dihydropteridine Reductase Activities in Patients with Thyroid and Breast Disorders. Pteridines. 2010;21:72–8. 77. Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-tryptophan: Basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009;2(1):45–60. 78. Sainio EL, Pulkki K, Young SN. L-Tryptophan: Biochemical, nutritional and pharmacological aspects. Amino Acids. 1995;21–47. 79. L-Tryptophan [Internet]. Available at: https://www.sigmaaldrich.com/TR/en/substance/ltryptophan2042373223 80. L-Kynurenine [Internet]. Available at: https://www.sigmaaldrich.com/TR/en/product/sigma/k8625 81. Gürcü S. Dı̇yabet hastalarinda pterı̇dı̇nlerı̇n ve ı̇lgı̇lı̇ yolaklarin değerlendı̇rı̇lmesı̇. Hacettepe Üniversitesi; 2018. 82. Abd El-Fattah EE. IDO/kynurenine pathway in cancer: possible therapeutic approaches. J Transl Med. 2022;20(1):1–13. 83. King NJC, Thomas SR. Molecules in focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007;39(12):2167–72. 84. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today. 1999;20(10):469–73. 85. Obara-Michlewska M. The tryptophan metabolism, kynurenine pathway and oxidative stress – implications for glioma pathobiology. Neurochem Int. 2022;158. 86. Davis I, Liu A. What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? Expert Rev Neurother. 2015;15(7):719–21. 87. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364(1–2):82– 90. 88. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, vd. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: Relationship to CNS immune responses and 72 depression. Mol Psychiatry. 2010;15(4):393–403. 89. Geng J, Liu A. Heme-dependent dioxygenases in tryptophan oxidation. Arch Biochem Biophys. 2014;544:18–26. 90. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119:197–209. 91. Kayaoğlu MY, Girgin G, Solmaz İ, Baydar T, Anlar B. Urine neopterin in childhood acute demyelinating diseases: Potential for differential diagnosis. Mult Scler Relat Disord. 2022;59(103662). 92. Girgin G, Palabıyık-Yücelik SS, Sipahi H, Kılıçarslan B, Ünüvar S, Tutkun E, vd. Mercury exposure, neopterin profile, and tryptophan degradation in dental technicians. Pteridines. 2022;33:32–8. 93. Sabuncuoğlu S, Öztaş Y, Yalçınkaya A, Ünal S, Baydar T, Girgin G. The increased neopterin content in turkish pediatric patients with sickle cell anemia. Ann Hematol. 2020;99:41–7. 94. Gürcü S, Girgin G, Yorulmaz G, Kılıçarslan B, Efe B, Baydar T. Neopterin and biopterin levels and tryptophan degradation in patients with diabetes. Sci Rep. 2020;10. 95. Başaran N, Ündeğer Ü. Effects of lead on immune parameters in occupationally exposed workers. Am J Ind Med. 2000;38(3):349–54. 96. Cavaleri D, Bartoli F, Capogrosso, Chiara A. Guzzi P, Moretti F, Riboldi I, Misiak B, vd. Blood concentrations of neopterin and biopterin in subjects with depression: A systematic review and meta-analysis. Prog Neuro Psychopharmacology Biol Psychiatry. 2023;120. 97. Mourad B, Teleb H. ALTERATION OF THE IMMUNE FUNCTIONS AMONG WORKERS OF SECONDART ALUMINUM SMELTING. Egypt J Occup Med. 2023;47(1):19–34. 98. Ahmad I, Khan B, Khan S, Khan MT, Schwab AP. Assessment of lead exposure among automobile technicians in Khyber Pakhtunkhwa, Pakistan. Sci Total Environ. 2018;633:293–9. 99. Himani G, Kumar R, Ansari JA, Mahdi AA, Sharma D, Karunanand B, vd. Blood Lead Levels in Occupationally Exposed Workers Involved in Battery Factories of Delhi-NCR Region: Effect on Vitamin D and Calcium Metabolism. Indian J Clin Biochem. 2020;35(1):80–7. 100. Basit S, Karim N, Munshi AB. Occupational lead toxicity in battery workers. Pakistan J Med Sci. 2015;31(4):775–80.tr_TR
dc.identifier.urihttp://hdl.handle.net/11655/29494
dc.description.abstractMuhammetli S., The Effect of Lead Exposure on Neopterin Levels in Metal Recycling Industry Workers, Hacettepe University Graduate School of Health Sciences Pharmacy Department of Pharmaceutical Toxicology Program Master of Science Thesis, Ankara, 2023. Lead is one of the life-threatening heavy metals that can be found in detectable concentrationsin different compartments of the human body after exposure. In industry, lead is widely used in many areas such as battery, metal and mining. One of the important business lines in which occupational exposure to toxic metals, mainly lead, may occur isthe “Recycling Sector”. Neopterin is a pteridine derivative that can be used as an early biomarker in various disorders such as tissue rejection, human immunodeficiency virus, multi-organ failure, sepsis, and cancer. In addition to neopterin release, indolamine 2,3-dioxygenase (IDO) enzyme, which plays a role in the rate-limiting step of the kynurenine pathway, is also induced by cellular immune activation. In this thesis, the relationship between blood lead levels and urinary neopterin, biopterin, manganese, cadmium and serum neopterin, kynurenine and tryptophan concentrations were evaluated in participants working in the recycling industry. It was found that urinary neopterin, lead, manganese and cadmium levels changed significantly with the increase in blood lead levels (all; p<0.05). Within the scope of the thesis, it was determined that exposure to heavy metals, especially lead, in the recycling sector affects the pteridine and kynurenine pathways.tr_TR
dc.language.isoturtr_TR
dc.publisherSağlık Bilimleri Enstitüsütr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectKurşuntr_TR
dc.subjectNeopterintr_TR
dc.subjectGeri Dönüşüm Sektörütr_TR
dc.subjectMetal Toksisitesitr_TR
dc.subject.lcshBilgi kaynaklarıtr_TR
dc.titleMetal Geri Dönüşüm Sektörü Çalışanlarında Kurşun Maruziyetinin Neopterin Düzeylerine Etkisitr_TR
dc.typeinfo:eu-repo/semantics/masterThesistr_TR
dc.description.ozetMuhammetli S., Metal Geri Dönüşüm Sektörü Çalışanlarında Kurşun Maruziyetinin Neopterin Düzeylerine Etkisi, Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü Farmasötik Toksikoloji Programı Yüksek Lisans Tezi, Ankara, 2023. Kurşun, maruziyeti sonrasında insan vücudunda farklı kompartmanlarda analiz edilebilir konsantrasyonlarda bulunabilen ve yaşamı tehdit eden ağır metallerden biridir. Endüstride akü, metal ve madencilik gibi birçok alanda yaygın olarak kullanımı söz konusudur. Kurşun başta olmak üzere toksik metallere mesleki maruziyetin söz konusu olabileceği önemli iş kollarından biri “Geri Dönüşüm Sekötürü”dür. Neopterin, doku reddi, insan immün yetmezlik virüsü, çoklu organ yetmezliği, sepsis, kanser gibi çeşitli sağlık sorunlarında erken biyogösterge olarak kullanılabilen bir pteridin türevidir. Hücresel immün aktivasyon ile neopterin salımının yanı sıra kinürenin yolağında hız kısıtlayıcı basamakta rol alan indolamin 2,3-dioksijenaz (IDO) enzimi de indüklenir. Bu tez çalışmasında, geri dönüşüm sektöründe çalışan katılımcılarda kan kurşun düzeyleri ile idrar neopterin, biyopterin, mangan, kadmiyum ve serum neopterin, kinürenin ve triptofan konsantrasyonları arasındaki ilişki değerlendirilmiştir. Katılımcıların kan kurşun düzeylerinin artması ile idrar neopterin, kurşun, mangan ve kadmiyum düzeylerinin anlamlı olarak değiştiği bulunmuştur (tümü; p<0,05). Bu tez kapsamında elde edilen sonuçlar ile geri dönüşüm sektöründe kurşun başta olmak üzere ağır metal maruziyetinin pteridin ve kinürenin yolağını etkilediği belirlenmiştir.tr_TR
dc.contributor.departmentFarmasötik Toksikolojitr_TR
dc.embargo.termsAcik erisimtr_TR
dc.embargo.lift2023-03-16T11:19:38Z
dc.fundingYoktr_TR
dc.subtypeworkingPapertr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster